In the morning edition of Kyoto Shimbun on October 15th, 2020 (Economy section, Page 15), the conclusion of the research collaboration agreement between Rebirthel and Fujita Health University was reported.
In the article entitled “Research on a novel therapy for the novel coronavirus infection using iPS cells”, it is introduced that Rebirthel is conducting the research to develop a novel therapy for the novel coronavirus infection using killer T cells that are regenerated from iPS cells in collaboration with Fujita Health University. High efficacy of therapy can be expected when T cell are administered to a patient prior to an aggravation of pneumonia. The article says that our development is the first in the world to use iPS cells for a therapy for the novel coronavirus infection.
Rebirthel has made the press release to announce this agreement on October 14th, 2020.
Link to the article (Only in Japanese)